AAPL299.77+1.76 (+0.59%) ▲|ABBV230.63+14.14 (+6.53%) ▲|ABT87.83-0.59 (-0.66%) ▼|ACN121.53-6.45 (-5.04%) ▼|ADBE193.54-1.63 (-0.83%) ▼|AMAT627.06+9.95 (+1.61%) ▲|AMD546.40+9.03 (+1.68%) ▲|AMGN342.18+4.58 (+1.36%) ▲|AMT177.24+1.19 (+0.68%) ▲|AMZN233.57-10.82 (-4.43%) ▼|AVGO394.92-16.43 (-3.99%) ▼|AXP337.15-0.86 (-0.25%) ▼|BA221.59-1.13 (-0.51%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG165.27-6.51 (-3.79%) ▼|BLK1,050.06-0.03 (0.00%) ▼|BMY54.35+0.35 (+0.64%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B490.10+0.64 (+0.13%) ▲|C145.74+2.68 (+1.87%) ▲|CAT1,016.41+30.59 (+3.10%) ▲|CL90.52+1.04 (+1.16%) ▲|CMCSA22.41-0.03 (-0.11%) ▼|COF199.29-2.24 (-1.11%) ▼|COP109.01+1.27 (+1.18%) ▲|COST950.35-1.10 (-0.12%) ▼|CRM149.09-2.69 (-1.77%) ▼|CSCO121.05+1.51 (+1.26%) ▲|CVS102.59+4.27 (+4.34%) ▲|CVX173.80+0.17 (+0.10%) ▲|DE603.46+14.22 (+2.41%) ▲|DHR175.83-1.34 (-0.76%) ▼|DIS102.88-1.01 (-0.97%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.68+0.02 (+0.01%) ▲|FDX329.82+4.84 (+1.49%) ▲|GD345.22-4.79 (-1.37%) ▼|GE357.640.00 (0.00%) ▼|GEV1,114.95+5.22 (+0.47%) ▲|GILD123.82+0.06 (+0.05%) ▲|GM82.58+3.29 (+4.15%) ▲|GOOG342.22-25.24 (-6.87%) ▼|GOOGL342.77-25.26 (-6.86%) ▼|GS1,094.90-1.66 (-0.15%) ▼|HD329.78-4.50 (-1.35%) ▼|HON231.08+2.07 (+0.90%) ▲|IBM246.19-2.92 (-1.17%) ▼|INTC140.02+6.03 (+4.50%) ▲|INTU258.80-8.20 (-3.07%) ▼|ISRG401.85-4.94 (-1.21%) ▼|JNJ230.89+2.50 (+1.09%) ▲|JPM330.36+5.14 (+1.58%) ▲|KO79.54+0.15 (+0.18%) ▲|LIN512.40+0.25 (+0.05%) ▲|LLY1,098.30-0.27 (-0.02%) ▼|LMT495.22-15.73 (-3.08%) ▼|LOW216.04-6.16 (-2.77%) ▼|LRCX394.19+5.15 (+1.32%) ▲|MA487.65-2.14 (-0.44%) ▼|MCD274.12-4.49 (-1.61%) ▼|MDLZ60.06-0.06 (-0.10%) ▼|MDT78.90-0.44 (-0.55%) ▼|META561.37-15.85 (-2.75%) ▼|MMM162.94+2.34 (+1.45%) ▲|MO69.98+0.86 (+1.24%) ▲|MRK113.73-0.15 (-0.13%) ▼|MS226.88+3.71 (+1.66%) ▲|MSFT371.46-7.94 (-2.09%) ▼|MU1,191.02+57.03 (+5.03%) ▲|NEE87.21+0.46 (+0.53%) ▲|NFLX74.12-3.26 (-4.22%) ▼|NKE43.52-1.68 (-3.72%) ▼|NOW93.18-1.86 (-1.96%) ▼|NVDA209.31-1.38 (-0.66%) ▼|ORCL178.82-5.47 (-2.97%) ▼|PEP141.71-0.31 (-0.22%) ▼|PFE25.11-0.10 (-0.38%) ▼|PG150.08-0.31 (-0.20%) ▼|PLTR122.33-6.14 (-4.78%) ▼|PM175.39-3.01 (-1.69%) ▼|QCOM228.57+2.46 (+1.09%) ▲|RTX181.93-3.67 (-1.98%) ▼|SBUX100.87+0.22 (+0.21%) ▲|SCHW91.86+0.16 (+0.17%) ▲|SO93.80+0.71 (+0.76%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.37+0.36 (+1.64%) ▲|TMO459.70-4.92 (-1.06%) ▼|TMUS180.80-0.87 (-0.48%) ▼|TSLA408.50+8.01 (+2.00%) ▲|TXN332.07+9.21 (+2.85%) ▲|UBER71.77+0.13 (+0.17%) ▲|UNH405.93+4.97 (+1.24%) ▲|UNP261.35+4.47 (+1.74%) ▲|UPS107.99+3.13 (+2.98%) ▲|USB58.85+0.71 (+1.21%) ▲|V330.32+3.08 (+0.94%) ▲|VZ45.65+0.28 (+0.62%) ▲|WFC83.42+1.22 (+1.48%) ▲|WMT117.70+0.52 (+0.44%) ▲|XOM137.76-0.05 (-0.04%) ▼|AAPL299.77+1.76 (+0.59%) ▲|ABBV230.63+14.14 (+6.53%) ▲|ABT87.83-0.59 (-0.66%) ▼|ACN121.53-6.45 (-5.04%) ▼|ADBE193.54-1.63 (-0.83%) ▼|AMAT627.06+9.95 (+1.61%) ▲|AMD546.40+9.03 (+1.68%) ▲|AMGN342.18+4.58 (+1.36%) ▲|AMT177.24+1.19 (+0.68%) ▲|AMZN233.57-10.82 (-4.43%) ▼|AVGO394.92-16.43 (-3.99%) ▼|AXP337.15-0.86 (-0.25%) ▼|BA221.59-1.13 (-0.51%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG165.27-6.51 (-3.79%) ▼|BLK1,050.06-0.03 (0.00%) ▼|BMY54.35+0.35 (+0.64%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B490.10+0.64 (+0.13%) ▲|C145.74+2.68 (+1.87%) ▲|CAT1,016.41+30.59 (+3.10%) ▲|CL90.52+1.04 (+1.16%) ▲|CMCSA22.41-0.03 (-0.11%) ▼|COF199.29-2.24 (-1.11%) ▼|COP109.01+1.27 (+1.18%) ▲|COST950.35-1.10 (-0.12%) ▼|CRM149.09-2.69 (-1.77%) ▼|CSCO121.05+1.51 (+1.26%) ▲|CVS102.59+4.27 (+4.34%) ▲|CVX173.80+0.17 (+0.10%) ▲|DE603.46+14.22 (+2.41%) ▲|DHR175.83-1.34 (-0.76%) ▼|DIS102.88-1.01 (-0.97%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.68+0.02 (+0.01%) ▲|FDX329.82+4.84 (+1.49%) ▲|GD345.22-4.79 (-1.37%) ▼|GE357.640.00 (0.00%) ▼|GEV1,114.95+5.22 (+0.47%) ▲|GILD123.82+0.06 (+0.05%) ▲|GM82.58+3.29 (+4.15%) ▲|GOOG342.22-25.24 (-6.87%) ▼|GOOGL342.77-25.26 (-6.86%) ▼|GS1,094.90-1.66 (-0.15%) ▼|HD329.78-4.50 (-1.35%) ▼|HON231.08+2.07 (+0.90%) ▲|IBM246.19-2.92 (-1.17%) ▼|INTC140.02+6.03 (+4.50%) ▲|INTU258.80-8.20 (-3.07%) ▼|ISRG401.85-4.94 (-1.21%) ▼|JNJ230.89+2.50 (+1.09%) ▲|JPM330.36+5.14 (+1.58%) ▲|KO79.54+0.15 (+0.18%) ▲|LIN512.40+0.25 (+0.05%) ▲|LLY1,098.30-0.27 (-0.02%) ▼|LMT495.22-15.73 (-3.08%) ▼|LOW216.04-6.16 (-2.77%) ▼|LRCX394.19+5.15 (+1.32%) ▲|MA487.65-2.14 (-0.44%) ▼|MCD274.12-4.49 (-1.61%) ▼|MDLZ60.06-0.06 (-0.10%) ▼|MDT78.90-0.44 (-0.55%) ▼|META561.37-15.85 (-2.75%) ▼|MMM162.94+2.34 (+1.45%) ▲|MO69.98+0.86 (+1.24%) ▲|MRK113.73-0.15 (-0.13%) ▼|MS226.88+3.71 (+1.66%) ▲|MSFT371.46-7.94 (-2.09%) ▼|MU1,191.02+57.03 (+5.03%) ▲|NEE87.21+0.46 (+0.53%) ▲|NFLX74.12-3.26 (-4.22%) ▼|NKE43.52-1.68 (-3.72%) ▼|NOW93.18-1.86 (-1.96%) ▼|NVDA209.31-1.38 (-0.66%) ▼|ORCL178.82-5.47 (-2.97%) ▼|PEP141.71-0.31 (-0.22%) ▼|PFE25.11-0.10 (-0.38%) ▼|PG150.08-0.31 (-0.20%) ▼|PLTR122.33-6.14 (-4.78%) ▼|PM175.39-3.01 (-1.69%) ▼|QCOM228.57+2.46 (+1.09%) ▲|RTX181.93-3.67 (-1.98%) ▼|SBUX100.87+0.22 (+0.21%) ▲|SCHW91.86+0.16 (+0.17%) ▲|SO93.80+0.71 (+0.76%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.37+0.36 (+1.64%) ▲|TMO459.70-4.92 (-1.06%) ▼|TMUS180.80-0.87 (-0.48%) ▼|TSLA408.50+8.01 (+2.00%) ▲|TXN332.07+9.21 (+2.85%) ▲|UBER71.77+0.13 (+0.17%) ▲|UNH405.93+4.97 (+1.24%) ▲|UNP261.35+4.47 (+1.74%) ▲|UPS107.99+3.13 (+2.98%) ▲|USB58.85+0.71 (+1.21%) ▲|V330.32+3.08 (+0.94%) ▲|VZ45.65+0.28 (+0.62%) ▲|WFC83.42+1.22 (+1.48%) ▲|WMT117.70+0.52 (+0.44%) ▲|XOM137.76-0.05 (-0.04%) ▼|
22.8 C
New York
Monday, June 22, 2026

Tag: therapies

newssourceFORcompanyinformationcontent1marketreleases

US NCI Sponsors Senhwa Biosciences’ Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for...

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®

AHMEDABAD, India, Aug. 7, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as...

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- XtalPi...

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 6, 2025 /PRNewswire/ -- XtalPi...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2025 by conference call on Monday, August 11, 2025 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an...

Immix Biopharma Announces Other Serious Diseases Strategy

– Dosing ongoing and planned in a handful of Other Serious Diseases (OSD) –

Brain Injury Association of America to Honor Centre for Neuro Skills’ Dr. Mark Ashley as Luminary of the Year

Brain Injury Association of America honors Centre for Neuro Skills' Dr. Mark Ashley as 2025 Luminary of the Year for contributions in brain injury field

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)

CORAL GABLES, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Small Cell Lung Cancer (SCLC) now include new additions involving Lambert Eaton myasthenic syndrome (LEMS), amifampridine (FIRDAPSE®), and the tests for PQ- and N-type voltage-gated calcium channel (VGCC) antibodies.

Fortrea Reports Second Quarter 2025 Results

For the three months ended June 30, 2025, from continuing operations:

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers